| abstract |
The invention relates to carbacyclins of general Formula I ##STR1## wherein R 1 is the residue CH 2 OH or ##STR2## with R 2 meaning a hydrogen atom, an alkyl, cycloalkyl, aryl residue, a ##STR3## or heterocyclic residue, or R 1 is the residue ##STR4## with R 3 meaning an alkanoyl or alkanesulfonyl residue of respectively 1-10 carbon atoms or the residue R 2 , or n R 1 is the residue ##STR5## wherein m is the number 1 or 2, X is an oxygen atom or a CH 2 -group, n A is a trans--CH═CH- or --.tbd.C--group, n W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the α- or β- position, n n is the number 1, 2, or 3, n D is a straight-chain alkylene group of 1-5 carbon atoms, n E is a --C.tbd.C---bond or a --CR 6 =CR 7 --group wherein R 6 and R 7 are different from each other and mean a hydrogen atom or an alkyl group of 1-5 carbon atoms or a hydrogen atom or a halogen atom, preferably chlorine, n R 4 is an alkyl, cycloalkyl, or optionally substituted arly group, or a heterocyclic group, n R 5 is a free or functionally modified hydroxy group, and n if R 2 means a hydrogen atom, the salts thereof with physiologically compatible bases; n to processes for the preparation thereof, and to the use thereof as blood-pressure-lowering agents. |